Verrica Pharmaceuticals Inc. - Common Stock (VRCA)
Frequently Asked Questions About Verrica Pharmaceuticals Inc. - Common Stock (VRCA)
Does Verrica Pharmaceuticals have any partnerships?
Yes, Verrica Pharmaceuticals has established partnerships with various organizations and research institutions. These collaborations often focus on advancing clinical trials, optimizing product development, and enhancing the company's research capabilities in dermatology.
How can investors learn more about Verrica Pharmaceuticals?
Investors can learn more about Verrica Pharmaceuticals by visiting the company's official website, reviewing investor relations materials, and accessing public financial disclosures. Regular updates about clinical trials, corporate developments, and financial performance are also available to the public.
How does Verrica Pharmaceuticals ensure product safety?
Verrica Pharmaceuticals adheres to rigorous clinical trial protocols and regulatory standards to ensure product safety and efficacy. This includes comprehensive preclinical and clinical testing to assess the safety profiles of its candidates before seeking approval for market entry.
How does Verrica Pharmaceuticals fund its operations?
Verrica Pharmaceuticals funds its operations through a combination of public equity offerings, partnerships, and grants. As a publicly traded company, it also has access to capital markets to support its research and development initiatives.
Is Verrica Pharmaceuticals publicly traded?
Yes, Verrica Pharmaceuticals is publicly traded on the NASDAQ stock exchange under the ticker symbol VRCA. Being a publicly traded company provides Verrica with capital resources to fund its research and development activities.
What are the company's goals for the future?
Verrica Pharmaceuticals aims to expand its pipeline of dermatological therapies by advancing its current candidates through clinical trials and exploring new therapeutic areas. The company is committed to addressing unmet medical needs and improving outcomes for patients with skin conditions.
What clinical trials are currently underway for Verrica's products?
Verrica Pharmaceuticals is conducting various clinical trials for its lead product, VP-102, and other pipeline candidates. These trials include studies designed to evaluate the safety, efficacy, and optimal use of their therapeutics in treating dermatological conditions.
What competitive advantages does Verrica have?
Verrica Pharmaceuticals benefits from its specialized focus on dermatology, proprietary drug formulations, and a dedicated research team. Its innovative approach to treatment and commitment to patient outcomes provide it with distinct competitive advantages in the biopharmaceutical landscape.
What does Verrica Pharmaceuticals Inc. do?
Verrica Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapeutics for dermatological conditions. The company aims to address unmet medical needs in areas such as dermatology by creating targeted treatments that improve the quality of life for patients.
What is the clinical stage of VP-102?
VP-102 is currently in clinical trials, with various studies aimed at demonstrating its efficacy and safety for the treatment of skin conditions such as warts. The company is working diligently to advance VP-102 through the development process to seek regulatory approval.
What is the mission statement of Verrica Pharmaceuticals?
The mission statement of Verrica Pharmaceuticals is to improve the lives of patients with skin conditions by developing innovative and effective therapies. The company is dedicated to addressing unmet medical needs and advancing the field of dermatology through scientific excellence.
What is the primary product developed by Verrica?
The primary product developed by Verrica Pharmaceuticals is VP-102, a topical drug designed for the treatment of common skin conditions such as warts. VP-102 utilizes a proprietary formulation that delivers its active ingredients to effectively target and treat the condition.
What is the primary therapeutic area of interest for Verrica?
The primary therapeutic area of interest for Verrica Pharmaceuticals is dermatology. The company is dedicated to addressing various skin conditions that lack effective treatment options, thus improving the quality of life for affected patients.
What markets does Verrica Pharmaceuticals target?
Verrica Pharmaceuticals primarily targets the dermatology market, focusing on conditions that affect the skin. This includes prevalent issues like warts and other dermatological disorders that require innovative treatment options for improved patient care.
What regulatory approvals has Verrica received?
Verrica Pharmaceuticals is working towards obtaining regulatory approvals from the U.S. Food and Drug Administration (FDA) for its key product candidates. As it progresses through clinical trials, the company submits necessary data to demonstrate safety and efficacy for eventual market authorization.
When was Verrica Pharmaceuticals founded?
Verrica Pharmaceuticals was founded in 2017. Since its inception, the company has focused on advancing drug candidates through clinical trials and into the market, aiming to provide effective dermatological treatments for patients.
Where is Verrica Pharmaceuticals headquartered?
Verrica Pharmaceuticals is headquartered in West Chester, Pennsylvania. The company's strategic location allows it to engage with numerous research and clinical institutions as it works on advancing its drug development initiatives.
Who are the key executives at Verrica Pharmaceuticals?
Key executives at Verrica Pharmaceuticals include Chief Executive Officer Dr. David C. Domzalski, Chief Financial Officer Mr. Michael J. Mullen, and Chief Medical Officer Dr. Joseph A. Gulfo. These leaders bring extensive experience in biotechnology, pharmaceuticals, and dermatology to the company.
Who are Verrica's main competitors?
Verrica Pharmaceuticals operates in a competitive landscape with several biopharmaceutical companies focused on dermatology. Its main competitors include those developing similar topical therapies for skin conditions, as well as larger pharmaceutical firms with established dermatology portfolios.
What is the current price of Verrica Pharmaceuticals Inc. - Common Stock?
The current price of Verrica Pharmaceuticals Inc. - Common Stock is 0.4750
When was Verrica Pharmaceuticals Inc. - Common Stock last traded?
The last trade of Verrica Pharmaceuticals Inc. - Common Stock was at 2:55 pm EDT on April 4th, 2025
What is the market capitalization of Verrica Pharmaceuticals Inc. - Common Stock?
The market capitalization of Verrica Pharmaceuticals Inc. - Common Stock is 19.93M
How many shares of Verrica Pharmaceuticals Inc. - Common Stock are outstanding?
Verrica Pharmaceuticals Inc. - Common Stock has 41.96M shares outstanding.